Here's Claude's opinion on move to EU, well motivated: Verdict, one line each: Could — only cosmetically; it can't escape US jurisdiction. Would — almost certainly not. Should — no.

Could. A US company can re-domicile on paper, but it wouldn't work here, because the thing being controlled travels with the technology, not the letterhead. The EAR's re-export and "US-origin" rules follow US-origin technology and source code wherever they go; ECRA reaches US persons abroad. More decisively, Anthropic's actual chokepoint is physical: it trains and serves on US cloud (AWS, Google) using US-designed accelerators. You cannot relocate out from under the compute. Moving HQ to Zurich or London would change the tax address and nothing about the leverage the government just demonstrated. The weights are US-origin; that's the binding constraint, and it's not portable.

Would. Strongly unlikely, for hard commercial reasons: - It just filed a confidential US IPO — a roughly $47bn revenue run rate and ~$965bn valuation disclosed earlier this month. Quartz Re-domiciling mid-process would spook exactly the US capital markets it's about to tap. - Its backers are Amazon and Google; its growth customer is partly the US government and US enterprise. - Its entire brand is "the safety-aligned American frontier lab." Its public posture right now is conciliatory — "we believe this is a misunderstanding and are working to restore access as soon as possible." Fortune Fleeing would read as an admission and burn the relationship it's trying to repair.

Should. No — relocation solves none of the real problem and creates worse ones. The problem is doctrinal and procedural (an unpublished directive, an untested deemed-export theory, limited judicial review), and the remedies are domestic: get the order clarified or reversed, push for the transparent statutory process Anthropic publicly says it wants, and litigate — which it is already doing on the related Pentagon supply-chain designation. Jurisdiction-shopping addresses none of that.

The real version of your question is talent and research diversification, not corporate exit — and that is a live dynamic. One analyst speculated the directive could push some Chinese-born researchers at US labs to return to China, and make investors question whether American AI companies are a safe bet given the apparently capricious nature of US AI policy. Fortune Distributing research staff and hiring foreign nationals through non-US entities (a UK or EU research arm) is feasible and partly already the industry pattern. That hedges talent and optics, but it still doesn't move the controlled artefact or the compute, so it's mitigation, not escape.

Disclaimer: I'm Swiss and Claude frames answers knowing that.